This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Balakrishnan, A. Articles by Bardelli, A. Search for Related Content PubMed PubMed Citation Articles by Balakrishnan, A. Articles by Bardelli, A.

Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma

¹ Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo, Italy; Departments of ² Neurosurgery and ³ Neuropathology, Academic Medical Center, University of Amsterdam, the Netherlands; ⁴ Department of Experimental Oncology, Instituto Nazionale Tumori; ⁵ FIRC Institute of Molecular Oncology, Milan, Italy; and ⁶ Department of Pathology, Section of Anatomic Pathology, University of Verona, Verona, Italy

Requests for reprints: Alberto Bardelli, Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Torino, Medical School, Str prov 142 Km 3.95, Candiolo (TO), ZIP 10060, Italy. Phone: 39-119933235; Fax: 39-11993225; E-mail: a.bardelli{at}unito.it.

A recent systematic sequence analysis of well-annotated human protein coding genes or consensus coding sequences led to the identification of 189 genes displaying somatic mutations in breast and colorectal cancers. Based on their mutation prevalence, a subset of these genes was identified as cancer candidate (CAN) genes as they could be potentially involved in cancer. We evaluated the mutational profiles of 19 CAN genes in the highly aggressive tumors: glioblastoma, melanoma, and pancreatic carcinoma. Among other changes, we found novel somatic mutations in EPHA3, MLL3, TECTA, FBXW7, and OBSCN, affecting amino acids not previously found to be mutated in human cancers. Interestingly, we also found a germline nucleotide variant of OBSCN that was previously reported as a somatic mutation. Our results identify specific genetic lesions in glioblastoma, melanoma, and pancreatic cancers and indicate that CAN genes and their mutational profiles are tumor specific. Some of the mutated genes, such as the tyrosine kinase EPHA3, are clearly amenable to pharmacologic intervention and could represent novel therapeutic targets for these incurable cancers. We also speculate that similar to other oncogenes and tumor suppressor genes, mutations affecting OBSCN could be involved in cancer predisposition. [Cancer Res 2007;67(8):3545–50]

This article has been cited by other articles:

				A. P. Kyritsis, M. L. Bondy, J. S. Rao, and C. Sioka Inherited predisposition to glioma Neuro Oncology, November 23, 2009; (2009) nop011v1. [Abstract] [Full Text] [PDF]

				J. Lee, D.-H. Kim, S. Lee, Q.-H. Yang, D. K. Lee, S.-K. Lee, R. G. Roeder, and J. W. Lee A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4 PNAS, May 26, 2009; 106(21): 8513 - 8518. [Abstract] [Full Text] [PDF]

				M. Lackmann and A. W. Boyd Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity? Sci. Signal., April 15, 2008; 1(15): re2 - re2. [Abstract] [Full Text] [PDF]

				J. E. Ruhe, S. Streit, S. Hart, C.-H. Wong, K. Specht, P. Knyazev, T. Knyazeva, L. S. Tay, H. L. Loo, P. Foo, et al. Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines Cancer Res., December 1, 2007; 67(23): 11368 - 11376. [Abstract] [Full Text] [PDF]